Observational Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Apr 14, 2021; 27(14): 1497-1506
Published online Apr 14, 2021. doi: 10.3748/wjg.v27.i14.1497
Figure 1
Figure 1 Flowchart of patient inclusion. CHB: Chronic hepatitis B; NAs: Nucleos(t)ide analogs.
Figure 2
Figure 2  Distribution of age and consolidation periods of patients with hepatitis B e antigen loss.
Figure 3
Figure 3 Cumulative virological relapse rates. Cumulative virological relapse rates in A: Hepatitis B e antigen (HBeAg) loss patients with hepatitis B surface antigen at cessation ≥ 100 IU/mL and < 100 IU/mL; B: HBeAg loss patients with consolidation periods ≥ 24 mo and < 24 mo. HBsAg: Hepatitis B surface antigen.
Figure 4
Figure 4 Cumulative virological relapse rates in patients with hepatitis B e antigen loss and seroconversion. HBeAg: Hepatitis B e antigen.